 | Up a level |
Sacher, Adrian; LoRusso, Patricia; Patel, Manish R; Miller, Wilson H; Garralda, Elena; Forster, Martin D; Santoro, Armando; Falcon, Alejandro; Kim, Tae Won; Paz-Ares, Luis; Bowyer, Samantha; de Miguel, Maria; Han, Sae-Won; Krebs, Matthew G; Lee, Jong-Seok; Cheng, Michael L; Arbour, Kathryn; Massarelli, Erminia; Choi, Yoonha; Shi, Zhen; ... (2023). Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. The New England journal of medicine, 389(8), pp. 710-721. Massachusetts Medical Society 10.1056/NEJMoa2303810
Peters, Solange; Gettinger, Scott; Johnson, Melissa L; Jänne, Pasi A; Garassino, Marina C; Christoph, Daniel; Toh, Chee Keong; Rizvi, Naiyer A; Chaft, Jamie E; Carcereny Costa, Enric; Patel, Jyoti D; Chow, Laura Q M; Koczywas, Marianna; Ho, Cheryl; Früh, Martin; van den Heuvel, Michel; Rothenstein, Jeffrey; Reck, Martin; Paz-Ares, Luis; Shepherd, Frances A; ... (2017). Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of clinical oncology, 35(24), pp. 2781-2789. American Society of Clinical Oncology 10.1200/JCO.2016.71.9476
